Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Beijing Institute of Biological Products/Wuhan Institute of Biological Products

Next Previous
X
Search
Drug Profile

Coronavirus vaccine - Beijing Institute of Biological Products/Wuhan Institute of Biological Products

Alternative Names: 2019-CoV - Wuhan Institute of Biological Products; BBIBP-CorV - Inactivated SARS-CoV-2 vaccine; BBIBP-CorV Vaccine; COVAX; COVID-19 Vaccine - Sinopharm; Inactivated COVID-19 vaccine - Wuhan Institute of Biological Products; SARS-CoV-2 vaccine - Wuhan Institute of Biological Products; Sinopharm CNBG COVID-19 vaccine; Vero cell - Wuhan Institute of Biological Products

Latest Information Update: 28 Jun 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Institute of Biological Products; Wuhan Institute of Biological Products
  • Developer Beijing Institute of Biological Products; China National Biotec Group; Sinopharm
  • Class COVID-19 vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 29 Apr 2022 China National Biotec Group completes a phase-III trial in COVID-2019 infections (Prevention, In children, In adults, In the elderly, In adolescents) in United Arab Emirates (IM, Injection) (NCT04917523)
  • 23 Feb 2022 Registered (Emergency use authorization) for COVID-2019 infections (In the elderly, Prevention, In adults) in Pakistan (Parenteral) (NCT05162482)
  • 18 Feb 2022 Preregistered (Emergency Use Authorization) for COVID-2019 infections (Prevention, In adults, In the elderly) in Pakistan (Parenteral) (NCT05162482)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top